Volume 18, Number 1—January 2012
CME ACTIVITY - Research
Accelerating Control of Pertussis in England and Wales
, Gayatri Amirthalingam, Nick Andrews, Norman K. Fry, Robert C. George, Timothy Harrison, and Elizabeth Miller
Table 4
Estimated effectiveness of a 3-dose pertussis vaccine schedule among case-patients with culture- or PCR-confirmed pertussis, by vaccine cohort and age group, England, 1998–2009*
| Vaccine cohort† | Age group of pertussis case-patients |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12–39 mo |
40–59 mo |
5–9 y |
10–16 y |
||||||||
| No. vaccinated/ no. total | % VE (95% CI) | No. vaccinated/ no. total | % VE (95% CI) | No. vaccinated/ no. total | % VE (95% CI) | No. vaccinated/ no. total | % VE (95% CI) | ||||
| 1 | – | – | – | – | 5/8 | 92 (48.8–98.5) | 15/26 | 87.2 (69.2–94.5) | |||
| 2 | 25/52 | 97.7 (95.9–98.7) | 38/57 | 95.7‡ (92.2–97.6) | 94/125 | 92.8‡ (88.8–95.2) | 39/44 | 82.0‡ (41.4–92.9) | |||
| 3 | 12/37 | 98.7 (97.4–99.4) | 2/5 | 98.4§ (85.9–99.9) | 1/4 | 99.2§ (89.9–100.0) | – | – | |||
| 4 | 8/21 | 98.4 (95.9–99.4) | 1/2 | – | 0/1 | – | – | – | |||
| 5 | 11/19 | 96.6 (90.2–98.7) | – | – | – | – | – | – | |||
| Overall total | 56/129 | 98.1 (97.2–98.7) | 41/64 | 96.1 (93.3–97.7) | 100/138 | 93.4 (90.1–95.5) | 54/70 | 83.7 (69.5–90.8) | |||
*VE, vaccine effectiveness; –, no cases that met the criteria were identified during 1998–2009 and, therefore, VE could not be calculated, or case nos. were too small for calculation purposes.
†Vaccine cohorts: cohort 1, received diphtheria/tetanus/whole-cell pertussis vaccine (DTwP) at 3, 5, and 11 mo of age; cohort 2, received DTwP at 2, 3, and 4 mo of age; cohort 3, received DTwP or DTaP3 (DT/3-component acellular pertussis vaccine) at 2, 3, and 4 mo of age; cohort 4, received DTwP at 2, 3, 4 mo of age; cohort 5, received DTaP5 at 2, 3, and 4 mo of age.
‡VE mainly reflects 3 doses; however, some eligible children had received 4 doses.
§Some children were eligible for a booster vaccination; thus, VE is for 3 or 4 doses.